Cancer Biomarker Test Could Detect Mesothelioma Earlier
A new cancer biomarker test that promises to identify cancer in patients with “non-specific symptoms” could be the key to detecting mesothelioma earlier. Malignant mesothelioma is a deadly cancer caused by asbestos. The early symptoms of mesothelioma are usually vague and similar to other conditions. As a result, mesothelioma is frequently diagnosed in a late stage. But a cancer biomarker test developed in the UK could change that. The test looks for small molecules called metabolites in the blood. Its developers say it has the potential to find cancer earlier than other blood-based cancer tests. Non-Specific Symptoms Make Mesothelioma a Diagnostic Challenge Mesothelioma is a rare cancer. It is most common in people who worked or lived around asbestos in … Continue reading Cancer Biomarker Test Could Detect Mesothelioma Earlier
Patients Live Twice as Long with Less of this Biomarker for Pleural Mesothelioma
An enzyme that helps mop up the products of cellular oxidation might also serve as a powerful biomarker for pleural mesothelioma. People with the lowest levels of this enzyme survived longer with mesothelioma than those with higher levels. Glutathione peroxidase-1 (GPX-1) is an enzyme found in all cells. It helps keep toxins from building up inside cells. It also helps regulate certain cellular processes. But there is also evidence that GPX-1 may play a role in the development of cancer. Researchers in Egypt recently discovered that pleural mesothelioma tumors have more GPX-1 than the healthy tissue around them. The less they have, the better the prognosis. The findings suggest that GPX-1 could be a useful biomarker for pleural mesothelioma. Mesothelioma … Continue reading Patients Live Twice as Long with Less of this Biomarker for Pleural Mesothelioma
Genetic Mesothelioma Risk May Lead to Shorter Latency
A particular genetic risk for mesothelioma may be behind the few cases where cancer develops just a few years after asbestos exposure. That is the word from researchers at Australia’s Flinders University and the Asbestos Diseases Research Institute. Latency is the time it takes after exposure to a cancer-causing agent for signs of cancer to show up. Malignant mesothelioma has one of the longest latency periods of any cancer. In most cases, it takes about 40 years for mesothelioma to develop. As a result, mesothelioma is rare in people under 65. But, in rare cases, mesothelioma develops earlier in life. These cases have sometimes been dismissed as being unrelated to asbestos. But in a new journal article, mesothelioma experts from … Continue reading Genetic Mesothelioma Risk May Lead to Shorter Latency
Blood Test May Reveal History of Exposure to Asbestos
Small, non-coding bits of RNA in blood serum may offer a way to measure a person’s exposure to asbestos and predict their risk for mesothelioma. Malignant mesothelioma is just one of several types of cancer linked to exposure to asbestos. But, unless a person knows they have been exposed, doctors might not even think to look for it, even when a patient develops early symptoms. Researchers at Italy’s University of Ferrara have identified a microRNA in blood serum that can act as a biomarker for asbestos in the body. The discovery could lead to a blood test to identify high-risk people. Exposure to Asbestos and Malignant Mesothelioma Before asbestos, mesothelioma was virtually unheard of. In fact, when the first asbestos-exposed … Continue reading Blood Test May Reveal History of Exposure to Asbestos
Artificial Intelligence Tool Measures Mesothelioma Treatment Response
Scientists at the University of Glasgow in Scotland have developed an artificial intelligence tool that could revolutionize the way doctors plan and monitor mesothelioma treatment. The University team collaborated with Scottish firm Canon Medical Research Europe to develop an AI prototype for detecting pleural mesothelioma. Canon Medical specializes in medical imaging software. Pleural mesothelioma is a type of lung cancer caused by asbestos exposure. The new artificial intelligence tool is designed to find and measure mesothelioma tumors on CT scans. It can be challenging even for cancer experts to detect tiny changes in mesothelioma tumors. But the AI tool can quickly reveal how well or poorly a patient is doing on a treatment like chemotherapy. The sooner doctors know if … Continue reading Artificial Intelligence Tool Measures Mesothelioma Treatment Response
Researchers Discover How Three Enzymes Influence Mesothelioma Risk
University of Hawaii scientists have just released new research that helps explain how three enzymes may work together to determine mesothelioma risk. Most people who contract malignant mesothelioma have a history of asbestos exposure. But scientists still are not sure exactly why some people are at higher risk than others. Researcher Michele Carbone and his team at the University of Hawaii Cancer Center have spent years trying to understand the underlying mechanism of mesothelioma risk. Their new report is a big step forward. It shows how three molecules interact to determine a person’s risk profile. It also demonstrates how something as simple as aspirin might be used to modify that risk. Three Molecules That Influence Mesothelioma Risk BAP1 is a … Continue reading Researchers Discover How Three Enzymes Influence Mesothelioma Risk
Could Lipids Hold the Key to Improving the Mesothelioma Diagnostic Process?
A new Chinese report suggests that molecules called lipids could hold the key to improving the mesothelioma diagnostic process. Mesothelioma is rare and hard to treat. It is critical to diagnose it accurately and as early as possible for the best outcomes. But the mesothelioma diagnostic process can be complex and difficult. The Chinese researchers compared the amounts and types of lipids in the blood of mesothelioma patients to those in the blood of healthy people. They discovered five lipids that were higher in the mesothelioma patients and 29 that were lower. The information could help doctors refine the mesothelioma diagnostic process. It could also help them determine how a patient is doing on a particular treatment. Lipids and the … Continue reading Could Lipids Hold the Key to Improving the Mesothelioma Diagnostic Process?
Mesothelioma Blood Test Could Help Delay Time Between CT Scans
A mesothelioma blood test could make it possible to stretch the time between CT scans to monitor treatment progress. That is the conclusion from a team of cancer experts in Italy. The researchers compared the results of the SMRP mesothelioma blood test to CT scans and other prognostic indicators in pleural mesothelioma patients. Doctors typically use a set of criteria called mRECIST to assess how well a particular therapy is working. mRECIST includes measurements from CT scans. But CT scans are expensive, time-consuming, and expose patients to ionizing radiation. The goal of the new study was to see how closely SMRP levels correlated with mRECIST results. The team says the blood test appears to be accurate enough that it could … Continue reading Mesothelioma Blood Test Could Help Delay Time Between CT Scans
Mesothelioma Surgical Decisions: New Method May Make Them Easier
Cancer researchers in India and the UK have come up with a method for making better mesothelioma surgical decisions. The group focused on peritoneal mesothelioma, the second most common form of asbestos cancer. Peritoneal mesothelioma affects the membrane around the abdominal organs. It can spread throughout the abdomen. Some peritoneal mesothelioma patients get good results with cytoreductive surgery. But success depends on a number of factors such as how far cancer has spread and where mesothelioma tumors are located. The new decision-making tool reminds doctors of five important factors to consider when making mesothelioma surgical decisions for the best outcomes. It is based on the acronym PAUSE. Peritoneal Mesothelioma and the Promise of CRS/HIPEC Malignant mesothelioma is an especially aggressive … Continue reading Mesothelioma Surgical Decisions: New Method May Make Them Easier
Diagnostic Accuracy of Lung Fluid Tests for Mesothelioma
Researchers in Germany say the diagnostic accuracy of lung fluid tests for mesothelioma is high enough that they can be routinely used for diagnosis. Right now, if mesothelioma is suspected, doctors may order a fluid test first. If the fluid test (cytology) is positive, the doctor usually orders a tissue biopsy (histology) to confirm. But the German team says their study shows that the diagnostic accuracy of cytology is almost as good as histology for mesothelioma – especially when doctors consider the patient’s hyaluronic acid level, too. Scientists from several German institutions analyzed cytology tests from more than 4,500 suspected cases of pleural mesothelioma. They conclude that cytology is accurate enough to be used routinely for diagnosis. The Importance of … Continue reading Diagnostic Accuracy of Lung Fluid Tests for Mesothelioma
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!